Rohit Dhall

High Impact

Department Chairperson

UAMS

Last publication 2026 Last refreshed 2026-05-16

faculty

Neurology, College of Medicine

29 h-index 97 pubs 3,640 cited

Research Areas

Links

ORCID Research Group UAMS TRI Profile

OverviewAI-generated summary

Rohit Dhall's research focuses on neurodegenerative disorders, with a clinical emphasis on the diagnosis and management of conditions such as parkinsonism, dementias, dystonia, and tremor. His work also investigates novel diagnostics and therapeutics for neurological illnesses and aims to improve care delivery programs for individuals living with these conditions.

Dr. Dhall holds several leadership positions at the University of Arkansas for Medical Sciences (UAMS), including Department Chairperson of Neurology. He also directs UAMS' Parkinson Foundation Comprehensive Care Center and Cure PSP Center of Excellence, and co-directs the Multiple Systems Atrophy Center of Excellence. His scholarly output includes over 100 publications, with a citation count of 3,561 and an h-index of 28. Recent publications have examined the safety and efficacy of various pharmaceutical interventions for Parkinson's disease and Huntington's disease, as well as non-pharmacological approaches like vibrotactile stimulation.

Key collaborators include Tuhin Virmani, Aliyah Glover, and Lakshmi Pillai from UAMS, and Krishna Nalleballe from the University of Arkansas at Little Rock. Dr. Dhall leads a research group and is recognized as a highly cited researcher.

Research Overview

My clinical expertise in diagnosis and management of Neurodegenerative disorders, including parkinsonism, dementias, dystonia and tremor. My clinical research focuses on developing novel diagnostics and therapeutics, and developing and improving programs delivering care to people living with neurological illness. In addition to serving as Department Chair of Neurology, I direct UAMS' Parkinson Foundation Comprehensive Care Center, and CurePSP Center of Care, and co-direct the Multiple Systems Atrophy Center of Excellence at UAMS.

Metrics

h-index: 29
Publications: 97
Citations: 3,640

Selected Publications

The 201 Trial: a placebo-controlled randomized phase 2 study of safety and tolerance of the c-Abl kinase inhibitor risvodetinib in untreated Parkinson’s disease (2026)

DOI OpenAlex
Voice and Speech in Atypical Parkinsonian Disorders (2026)

DOI OpenAlex
Lessons Learned From a Delayed‐Start Trial of Modafinil for Freezing of Gait in Parkinson's Disease (2025)

DOI OpenAlex
A Qualitative Approach to Extract Diagnostic Patterns of Cognitive Impairment in Parkinson’s Disease (2025)

DOI OpenAlex
Transcutaneous Afferent Patterned Stimulation Provides Sustained Benefit in Essential Tremor (PROSPECT Study) (P1-5.002) (2025)

DOI OpenAlex
Safety and Efficacy of <scp>IPX203</scp> in Parkinson's Disease: The <scp>RISE‐PD Open‐Label</scp> Extension Study (2023)

6 citations DOI OpenAlex
Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial (2023)

112 citations DOI OpenAlex
A Randomized Phase 3 Study Comparing <scp>P2B001</scp> to its Components (Low‐Dose Extended‐Release Rasagiline and Pramipexole) and to Optimized Doses of Marketed Extended‐Release Pramipexole in Early Parkinson's Disease (2023)

4 citations DOI OpenAlex
Impedance trend from a symptomatic perielectrode cystic cavity following deep brain stimulation: illustrative case (2023)

2 citations DOI OpenAlex
Long-term Safety and Efficacy of IPX203 in Parkinson’s Disease Patients with Motor Fluctuations: A 9-Month Open-label Extension Trial (S32.006) (2023)

1 citation DOI OpenAlex
Improving levodopa delivery: IPX203, a novel extended-release carbidopa-levodopa formulation (2023)

12 citations DOI OpenAlex
Conversion to Hybrid Deep Brain Stimulation System to Enable Multi‐Contact Fractionation Can be Therapeutic (2022)

3 citations DOI OpenAlex
Clinical Efficacy and Dosing of Vibrotactile Coordinated Reset Stimulation in Motor and Non-motor Symptoms of Parkinson's Disease: A Study Protocol (2021)

3 citations DOI OpenAlex
Olfactory Deficits in the Freezing of Gait Phenotype of Parkinson's Disease (2021)

9 citations DOI OpenAlex
Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care (2021)

75 citations DOI OpenAlex

View all publications on OpenAlex →

Research Interests

Neurodegenerative Disorder; Parkinsonism; Parkinson's Disease; Dementia; Tremor; Dystonia; Chorea Syndromes; Deep Brain Stimulation

Grants & Funding

A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Intramuscular ABP-450 (prabotulinumtoxinA) Injection for the Treatment of Cervical Dystonia (IRB 262548) AEON Biopharma, Inc. - Pass Through: PPD Investigator Services, LLC Principal Investigator
58 Week Open-label Trial of Tavapadon in Parkinson's Disease (TemPO-4 Trial) (IRB 262509) Cerevel Therapeutics, LLC - Pass Through: Syneos Health Principal Investigator
No FP attached AbbVie Inc Principal Investigator
A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa- Treated Patients with Parkinson’s Disease Experiencing End of Dose “Wearing-Off” Biotie Therapies Inc. Principal Investigator
A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease (IRB 274673) Inhibikase Therapeutics, Inc. - Pass Through: IQVIA, Inc. Principal Investigator
PROSPECT: Prospective Study for Symptomatic Relief of ET with Cala Therapy (IRB 228403) Cala Health, Inc Principal Investigator
No FP attached Neuraly - Pass Through: Rho, Inc Principal Investigator
A Multicenter, Randomized, Active-Controlled, Double-Blind, Double-Dummy, Parallel Group Clinical Trial, Investigating the Efficacy, Safety and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison...(260930) NeuroDerm, Ltd. - Pass Through: Syneos Health Principal Investigator